Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San Diego, as well as notes on Geron, AbbVie and Deerfield Management. Food and Drug Administration Commissioner Robert Califf, speaking on a Wednesday panel, told BIO president John Crowley that he did not want to see…
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained momentum over the last several years. But some proponents believe that progress was undercut this week, when one of the field’s most advanced therapies hit a significant setback. On Tuesday, the Food and Drug Administration…
Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease drug donanemab is widely effective or should be restricted only to people who have deposits in their brains of a toxic protein called tau, according to documents released Thursday ahead of a key regulatory meeting…
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker GSK is investing further in nucleic acid drug development, reaching a deal to buy the San Diego-based Elsie Biotechnologies for as much as $50 million. GSK announced the deal Thursday, almost one year after beginning…
Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet, the companies said Wednesday. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also…
Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the National Institutes of Health that you may have missed from earlier this week. Eli Lilly’s drug tirzepatide — sold as Zepbound for obesity — continues to show promise in the liver disease MASH. Clinical trial…
Dive Brief: Illumina’s board of directors has approved a spinoff of Grail, targeting June 24 as the date the cancer blood test maker will regain its independence. Illumina agreed to divest the business it bought for $8 billion in 2021 after facing pressure from U.S and European antitrust regulators and activist investor Carl Icahn. Illumina,…
Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help treat post-traumatic stress disorder, recommending at a meeting Tuesday the agency hold off on an approval. The experts convened at the request of the FDA, which is reviewing a new drug application from Lykos Therapeutics,…
Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months, according to summary results revealed by developer Structure Therapeutics Monday. In the Phase 2a study, which enrolled 64 healthy individuals who were obese or overweight, Structure’s drug led to an average reduction in body weight…
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a line! Over the weekend at the American Society of Clinical Oncology’s annual meeting in Chicago, cancer researchers and doctors detailed fresh findings from hundreds of…
